CAMBRIDGE, England & EDINBURGH, Scotland & GRASSE, France--(BUSINESS WIRE)--Axol Bioscience Ltd. (Axol), a leading induced pluripotent stem cell (iPSC) technology provider for drug discovery, today announced it has fully acquired Phenocell SAS, a pioneer in iPSC-based products and bioassays for skin and retinal disorders..

英国剑桥、苏格兰爱丁堡和法国格拉斯——（商业新闻短讯）——Axol Bioscience Ltd.（Axol），一家领先的诱导多能干细胞（iPSC）药物发现技术提供商，今天宣布已完全收购Phenocell SAS，这是一家基于iPSC的皮肤和视网膜疾病产品和生物测定的先驱。

The acquisition extends Axol’s portfolio of iPSC-derived cell models, adding skin and human retinal iPSC-derived cell lines to its existing neuroscience, pain and touch, and cardiovascular products and services. Phenocell’s offering includes market-leading human iPSC-derived sebocytes and retinal pigment epithelium (RPE) and photoreceptor cells.

此次收购扩展了Axol的iPSC衍生细胞模型组合，将皮肤和人视网膜iPSC衍生细胞系添加到其现有的神经科学，疼痛和触觉以及心血管产品和服务中。Phenocell的产品包括市场领先的人类iPSC衍生的皮脂细胞和视网膜色素上皮（RPE）以及感光细胞。

Liam Taylor, CEO, Axol Bioscience, said: “Axol has previously operated in three areas of drug research and discovery: neuroscience, pain and touch, and cardiovascular drug discovery. This acquisition enables us to extend our product portfolio into ophthalmology and dermatology and offer iPSC-based skin and vision loss models.

Axol Bioscience首席执行官利亚姆·泰勒（Liam Taylor）表示：“Axol之前曾在药物研究和发现的三个领域开展业务：神经科学、疼痛和触觉以及心血管药物发现。此次收购使我们能够将产品组合扩展到眼科和皮肤科，并提供基于iPSC的皮肤和视力丧失模型。

We are delighted to welcome Phenocell to the Axol Bioscience family and look forward to building an even wider range of advanced in vitro models of human disease, combining our shared values and passion to accelerate drug discovery.”.

我们很高兴欢迎Phenocell加入Axol Bioscience家族，并期待着建立更广泛的先进人类疾病体外模型，结合我们共同的价值观和激情来加速药物发现。”

“We have built a unique set of products and services over the last decade to meet the growing requirements from the drug discovery and cosmetic industries to move from primary models to more consistent, human iPSC-derived models,” said Brigitte Onteniente, CEO and founder of Phenocell. “As part of Axol Bioscience we look forward to working with Liam and the team to develop a larger range of models, to serve a wider market.”.

Phenocell首席执行官兼创始人Brigitte Ontenente表示：“在过去十年中，我们建立了一套独特的产品和服务，以满足药物发现和化妆品行业不断增长的需求，从初级模型转向更一致的人类iPSC衍生模型。”。“作为Axol Bioscience的一部分，我们期待着与Liam和团队合作，开发更大范围的模型，以服务更广泛的市场。”

Financial terms of the agreement are not disclosed.

协议的财务条款未披露。

For more information on Axol, please visit https://axolbio.com/

有关Axol的更多信息，请访问https://axolbio.com/